Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial
@article{Biswal2020EfficacyOA, title={Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial}, author={Shibadas Biswal and C. Borja-Tabora and Luis Martinez Vargas and Derek Wallace}, journal={The Lancet}, year={2020}, volume={395}, pages={1423-1433} }
BACKGROUND
A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years.
METHODS
We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue
Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any… Expand
Conditions | Healthy Volunteers |
---|---|
Intervention | Biological, Drug |
Figures, Tables, and Topics from this paper
Paper Mentions
News Article
News Article
23 Citations
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial
- Medicine
- The Lancet
- 2020
- 8
Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study.
- Medicine
- The Journal of infectious diseases
- 2020
- 1
- PDF
The impact of serotype cross-protection on vaccine trials: DENVax as a case study
- 2020
- Highly Influenced
- PDF
The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study
- Medicine
- Vaccines
- 2020
- Highly Influenced
- PDF
An update on dengue vaccine development, challenges, and future perspectives
- Medicine
- Expert opinion on drug discovery
- 2020
Dengue vaccine development by the year 2020: challenges and prospects
- Biology, Medicine
- Current Opinion in Virology
- 2020
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
- Medicine
- Pathogens
- 2020
- 1
- Highly Influenced
- PDF
Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
- Biology, Medicine
- Tropical medicine and infectious disease
- 2020
- 1
- PDF
References
SHOWING 1-10 OF 31 REFERENCES
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial
- Medicine
- The Lancet
- 2020
- 8
Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
- Medicine
- The Journal of infectious diseases
- 2016
- 46
- PDF
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
- Medicine
- The Lancet
- 2014
- 697
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
- Medicine
- The Lancet. Infectious diseases
- 2018
- 29
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
- Medicine
- The New England journal of medicine
- 2019
- 63
Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds: A Randomized, Controlled, Phase II Trial in Latin America
- Medicine
- The Pediatric infectious disease journal
- 2013
- 65
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
- Medicine
- The Lancet. Infectious diseases
- 2014
- 97
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
- Medicine
- The Lancet. Infectious diseases
- 2017
- 42
- PDF
Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
- Medicine
- Vaccine
- 2015
- 37
Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
- Medicine
- The Journal of infectious diseases
- 2015
- 53
- PDF